Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Pembrolizumab vs Cetuximab Regimens in First-Line Recurrent/Metastatic HNSCC
jRCT2080222912Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2015
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of pembrolizumab in head and neck squamous cell carcinoma (HNSCC) and metastatic head and neck squamous cell carcinoma (mHNSCC) (3 arms), sponsored by Merck & Co. Started Jul 2015; status: completed.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)metastatic head and neck squamous cell carcinoma (mHNSCC)
Beyond the preview
Go deeper on jRCT2080222912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222912.